

References

M-79

1. Crossan C, Tsochatzis EA, Longworth L, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. *Health Technol Assess*. Jan 2015;19(9):1-409,v-vi.
2. Houot M, Ngo Y, Munteanu M, et al. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. *Aliment Pharmacol Ther*. Jan 2016;43(1):16-29.
3. Brener S. Transient elastography for assessment of liver fibrosis and steatosis: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2015;15(18):1-45.
4. Geng XX, Huang RG, Lin JM, et al. Transient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis. *Saudi J Gastroenterol*. Jul-Aug 2016;22(4):294-303.
5. Zeng X, Xu C, Wang Y, et al. The Diagnostic Value of FibroScan in Assessing Significant Liver Fibrosis in Patients with Chronic Hepatitis B. *The West Indian Medical Journal* [serial online]. May 15, 2015;65(1):106-110. Available from: MEDLINE Complete, Ipswich, MA.
6. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. *Current Gastroenterology Reports* [serial online]. February 2014;16(2):372. Available from: MEDLINE Complete, Ipswich, MA.
7. Li Y, Huang Y, Zhuang H, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. *Alimentary Pharmacology & Therapeutics* [serial online]. February 2016;43(4):458-469. Available from: MEDLINE Complete, Ipswich, MA.
8. ECRI Institute. FibroScan (EchoSens) Transient Elastography for Determining Optimal Candidates for Hepatitis C Pharmacotherapy. October 2014.
9. Lim JK, Flamm S, Sing S, Falck-Ytter YT, et al. American Gastroenterological Association institute guideline on the role of elastography in the evaluation of liver fibrosis. *Gastroenterology*. May 2017;152(6):1536-1543.
10. National Institute for Health and Care Excellence (NICE). Non-alcoholic fatty liver disease (NAFLD): assessment and management [NG49]. 2016.
11. National Institute for Health and Care Excellence (NICE). Hepatitis B (chronic): diagnosis and management [CG165]. 2013 June.
12. O'Shea RS, Dasarthy S, McCullough AJ, et al. Alcoholic liver disease. *Hepatology*. Jan 2010;51(1):307-328.
13. American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). Recommendations for Testing, Managing, and Treating Hepatitis C. 2016.

14. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Hgado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol*. Jul 2015;63(1):237-264.

[15. Salkic N, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B: A Meta-Analysis. Am J Gastroenterol. 2014; 109:796-809. doi:10.1038/ajg.2014.21.](#)

[16. Ergelen R, Yilmaz Y, Asedov R, Celikel C, Akin H, et al. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis. Abdom Radiol. 2016;41:1505–1510. doi: 10.1007/s00261-016-0699-6.](#)

[17. Ying H, Lu L, Jing D, Ni X. Accuracy of transient elastography in the assessment of chronic hepatitis C-related liver cirrhosis. Clin Invest Med. 2016; 38 \(5\): E150-E160.](#)